| HIV Infection |
1 |
1 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.98 |
| Patient Safety |
0 |
0.68 |
| Generics |
0 |
0.62 |
| Lipids Management |
0 |
0.62 |
| Social Determinants of Health |
0 |
0.56 |
| LGBT |
0 |
0.41 |
| Bone Density |
0 |
0.34 |
| Preexposure HIV Prophylaxis |
0 |
0.99 |
| Cost Sharing |
0 |
0.28 |
| Health Care Reform |
0 |
0.26 |
| Bone |
0 |
0.21 |
| Insurance |
0 |
0.21 |
| Kidney |
0 |
0.21 |
| Minerals |
0 |
0.21 |
| Cardiovascular Risk Management |
0 |
0.2 |
| Revenue and Practice Management |
0 |
0.16 |
| Allergy |
0 |
0.14 |
| Biomarker |
0 |
0.14 |
| Food and Drug Administration (FDA) |
0 |
0.14 |
| Grant |
0 |
0.14 |
| Health Care Quality, Access, and Evaluation |
0 |
0.14 |
| HIV Prevention |
0 |
0.14 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.12 |
| Outpatient Clinic |
0 |
0.12 |
| Adverse Effects |
0 |
0.07 |
| AIDS |
0 |
0.07 |
| Anus |
0 |
0.07 |
| Board Certification |
0 |
0.07 |
| Body Mass Index |
0 |
0.07 |
| California |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Hand |
0 |
0.07 |
| HIV Vaccine |
0 |
0.07 |
| Impairment |
0 |
0.07 |
| LDL Cholesterol |
0 |
0.07 |
| Medical Education |
0 |
0.07 |
| Minnesota |
0 |
0.07 |
| Nausea |
0 |
0.07 |
| Primary Care |
0 |
0.07 |
| Prophylaxis |
0 |
0.07 |
| Rural Health |
0 |
0.07 |
| Statins |
0 |
0.07 |
| Transgender |
0 |
0.07 |
| Vagina |
0 |
0.07 |
| Diarrhea |
0 |
0.05 |
| Hypertension |
0 |
0.05 |
| Vaccines |
0 |
0.05 |